Free Trial

IQVIA (IQV) Stock Forecast & Price Target

IQVIA logo
$203.38 -1.38 (-0.67%)
Closing price 03:59 PM Eastern
Extended Trading
$202.50 -0.88 (-0.43%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
5
Buy
19

Based on 24 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 5 have given a hold rating, 18 have given a buy rating, and 1 has given a strong buy rating for IQV.

Consensus Price Target

$234.57
15.33% Upside
According to the 24 analysts' twelve-month price targets for IQVIA, the average price target is $234.57. The highest price target for IQV is $270.00, while the lowest price target for IQV is $177.00. The average price target represents a forecasted upside of 15.33% from the current price of $203.38.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IQV Analyst Ratings Over Time

TypeCurrent Forecast
10/15/24 to 10/15/25
1 Month Ago
9/15/24 to 9/15/25
3 Months Ago
7/17/24 to 7/17/25
1 Year Ago
10/16/23 to 10/15/24
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
18 Buy rating(s)
18 Buy rating(s)
16 Buy rating(s)
12 Buy rating(s)
Hold
5 Hold rating(s)
6 Hold rating(s)
7 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$234.57$229.64$222.45$267.87
Forecasted Upside15.33% Upside23.33% Upside36.00% Upside14.97% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IQVIA Stock vs. The Competition

TypeIQVIAMedical CompaniesS&P 500
Consensus Rating Score
2.83
2.33
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside15.59% Upside1,039.48% Upside13.04% Upside
News Sentiment Rating
Positive News

See Recent IQV News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/9/2025HSBC
2 of 5 stars
Rajesh Kumar
Rajesh Kumar
Not Rated
UpgradeHoldBuy$195.00 ➝ $235.00+17.15%
10/9/2025Hsbc Global Res
5 of 5 stars
 UpgradeHoldStrong-Buy
10/8/2025Evercore ISI
3 of 5 stars
Boost TargetOutperform$220.00 ➝ $240.00+19.61%
10/8/2025Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingHold (C)
10/2/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$185.00 ➝ $200.00-1.93%
9/9/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$195.00 ➝ $225.00+19.86%
9/3/2025Redburn Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Target$214.00+17.92%
7/25/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$190.00 ➝ $225.00+13.90%
7/23/2025Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
7/23/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$185.00 ➝ $225.00+15.70%
7/23/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
7/23/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$209.00 ➝ $235.00+22.12%
7/23/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$159.00 ➝ $196.00+4.32%
5/22/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingNeutral
5/19/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$232.00 ➝ $177.00+25.40%
2/11/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$245.00 ➝ $250.00+24.05%
2/10/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$270.00 ➝ $270.00+31.00%
2/7/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$273.00 ➝ $261.00+24.95%
2/3/2025BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral
12/20/2024Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$250.00+30.53%
12/13/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$255.00 ➝ $235.00+17.54%
11/19/2024Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform$260.00 ➝ $248.00+28.58%
11/1/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$270.00 ➝ $265.00+27.09%
11/1/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$270.00 ➝ $255.00+22.30%
11/1/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$280.00 ➝ $250.00+20.00%
10/14/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$276.00+20.32%
7/31/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
2/15/2024Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyNeutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 11:17 PM ET.


Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, October 13, 2025. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

  • The stock has a consensus rating of "Moderate Buy" from analysts, indicating strong confidence in its future performance.
  • Recent earnings reports show that IQVIA Holdings Inc. exceeded revenue expectations, with a significant year-over-year revenue increase, suggesting robust business growth.
  • The current stock price is around $230, which is near the average target price set by analysts, indicating potential for further appreciation.
  • IQVIA Holdings Inc. operates in a growing sector, providing advanced analytics and technology solutions to the life sciences industry, which is increasingly reliant on data-driven insights.
  • The company has a strong return on equity, reflecting effective management and profitability, which can be attractive to investors looking for solid financial performance.

IQVIA
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

  • The company has a relatively high debt-to-equity ratio, which may indicate increased financial risk and reliance on borrowed funds.
  • Despite positive growth, the stock's price-to-earnings ratio is elevated, suggesting that it may be overvalued compared to its earnings potential.
  • Insider selling activity has been noted, which could signal a lack of confidence from those closest to the company.
  • The market is competitive, and any shifts in the life sciences sector could impact IQVIA Holdings Inc.'s market position and profitability.
  • While the company has shown growth, economic downturns or changes in healthcare regulations could adversely affect its business model.

IQV Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $234.57, with a high forecast of $270.00 and a low forecast of $177.00.

24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last year. There are currently 5 hold ratings, 18 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IQV shares.

According to analysts, IQVIA's stock has a predicted upside of 15.33% based on their 12-month stock forecasts.

Over the previous 90 days, IQVIA's stock had 3 upgrades by analysts.

Analysts like IQVIA more than other "medical" companies. The consensus rating for IQVIA is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how IQV compares to other companies.


This page (NYSE:IQV) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners